中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
A neuroimaging biomarker for striatal dysfunction in schizophrenia

文献类型:期刊论文

;
作者Li, Ang1,2,3,4; Zalesky, Andrew5,6,7; Yue, Weihua8,9,10; Howes, Oliver11,12; Yan, Hao8,9,10; Liu, Yong1,2,3,4; Fan, Lingzhong1,2,3,4; Whitaker, Kirstie J.13,14; Xu, Kaibin1,2,3; Rao, Guangxiang1,2,3,4
刊名NATURE MEDICINE ; NATURE MEDICINE
出版日期2020-03-23 ; 2020-03-23
卷号26期号:26页码:27
ISSN号1078-8956 ; 1078-8956
关键词TREATMENT-RESISTANT SCHIZOPHRENIA,RESTING-STATE FMRI,FUNCTIONAL CONNECTIVITY,DOPAMINE HYPOTHESIS,GENE-EXPRESSION,NETWORK TREATMENT-RESISTANT SCHIZOPHRENIA,RESTING-STATE FMRI,FUNCTIONAL CONNECTIVITY,DOPAMINE HYPOTHESIS,GENE-EXPRESSION,NETWORK
DOI10.1038/s41591-020-0793-8 ; 10.1038/s41591-020-0793-8
通讯作者Jiang, Tianzi(Jiangtz@nlpr.ia.ac.cn) ; Liu, Bing(bliu@nlpria.ac.cn)
英文摘要

Mounting evidence suggests that function and connectivity of the striatum is disrupted in schizophrenia(1-5). We have developed a new hypothesis-driven neuroimaging biomarker for schizophrenia identification, prognosis and subtyping based on functional striatal abnormalities (FSA). FSA scores provide a personalized index of striatal dysfunction, ranging from normal to highly pathological. Using inter-site cross-validation on functional magnetic resonance images acquired from seven independent scanners (n = 1,100), FSA distinguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensitivity, 79.3%; specificity, 81.5%). In two longitudinal cohorts, inter-individual variation in baseline FSA scores was significantly associated with antipsychotic treatment response. FSA revealed a spectrum of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most severe in schizophrenia, milder in bipolar disorder, and indistinguishable from healthy individuals in depression, obsessive-compulsive disorder and attention-deficit hyperactivity disorder. Loci of striatal hyperactivity recapitulated the spatial distribution of dopaminergic function and the expression profiles of polygenic risk for schizophrenia. In conclusion, we have developed a new biomarker to index striatal dysfunction and established its utility in predicting antipsychotic treatment response, clinical stratification and elucidating striatal dysfunction in neuropsychiatric disorders. A new cross-validated neuroimaging biomarker that reflects striatal dysfunctioning can be used to distinguish patients with schizophrenia from healthy controls, and is associated with treatment response to antipsychotics.

;

Mounting evidence suggests that function and connectivity of the striatum is disrupted in schizophrenia(1-5). We have developed a new hypothesis-driven neuroimaging biomarker for schizophrenia identification, prognosis and subtyping based on functional striatal abnormalities (FSA). FSA scores provide a personalized index of striatal dysfunction, ranging from normal to highly pathological. Using inter-site cross-validation on functional magnetic resonance images acquired from seven independent scanners (n = 1,100), FSA distinguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensitivity, 79.3%; specificity, 81.5%). In two longitudinal cohorts, inter-individual variation in baseline FSA scores was significantly associated with antipsychotic treatment response. FSA revealed a spectrum of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most severe in schizophrenia, milder in bipolar disorder, and indistinguishable from healthy individuals in depression, obsessive-compulsive disorder and attention-deficit hyperactivity disorder. Loci of striatal hyperactivity recapitulated the spatial distribution of dopaminergic function and the expression profiles of polygenic risk for schizophrenia. In conclusion, we have developed a new biomarker to index striatal dysfunction and established its utility in predicting antipsychotic treatment response, clinical stratification and elucidating striatal dysfunction in neuropsychiatric disorders. A new cross-validated neuroimaging biomarker that reflects striatal dysfunctioning can be used to distinguish patients with schizophrenia from healthy controls, and is associated with treatment response to antipsychotics.

WOS关键词TREATMENT-RESISTANT SCHIZOPHRENIA ; TREATMENT-RESISTANT SCHIZOPHRENIA ; RESTING-STATE FMRI ; FUNCTIONAL CONNECTIVITY ; DOPAMINE HYPOTHESIS ; GENE-EXPRESSION ; NETWORK ; PSYCHOSIS ; RISK ; DYSCONNECTIVITY ; DISORDER ; RESTING-STATE FMRI ; FUNCTIONAL CONNECTIVITY ; DOPAMINE HYPOTHESIS ; GENE-EXPRESSION ; NETWORK ; PSYCHOSIS ; RISK ; DYSCONNECTIVITY ; DISORDER
资助项目National Key Basic Research and Development Program (973)[2011CB707800] ; National Key Basic Research and Development Program (973)[2011CB707800] ; National Key Research and Development Plan[2016YFC0904300] ; Strategic Priority Research Program of Chinese Academy of Science[XDB32020200] ; Natural Science Foundation of China[81771451] ; National Key Research and Development Plan[2016YFC0904300] ; Strategic Priority Research Program of Chinese Academy of Science[XDB32020200] ; Natural Science Foundation of China[81771451]
WOS研究方向Biochemistry & Molecular Biology ; Biochemistry & Molecular Biology ; Cell Biology ; Research & Experimental Medicine ; Cell Biology ; Research & Experimental Medicine
语种英语 ; 英语
出版者NATURE PUBLISHING GROUP ; NATURE PUBLISHING GROUP
WOS记录号WOS:000521529700004 ; WOS:000521529700004
资助机构National Key Basic Research and Development Program (973) ; National Key Basic Research and Development Program (973) ; National Key Research and Development Plan ; Strategic Priority Research Program of Chinese Academy of Science ; Natural Science Foundation of China ; National Key Research and Development Plan ; Strategic Priority Research Program of Chinese Academy of Science ; Natural Science Foundation of China
源URL[http://ir.ia.ac.cn/handle/173211/38706]  
专题自动化研究所_脑网络组研究中心
通讯作者Jiang, Tianzi; Liu, Bing
作者单位1.Chinese Acad Sci, Brainnetome Ctr, Beijing, Peoples R China
2.Chinese Acad Sci, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China
3.Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing, Peoples R China
4.Chinese Acad Sci, Ctr Excellence Brain Sci & Intelligence Technol, Shanghai, Peoples R China
5.Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia
6.Melbourne Hlth, Melbourne, Vic, Australia
7.Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia
8.Peking Univ, Sixth Hosp, Inst Mental Hlth, Beijing, Peoples R China
9.Peking Univ, Sixth Hosp, Minist Hlth, Key Lab Mental Hlth, Beijing, Peoples R China
10.Peking Univ, Sixth Hosp, Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Li, Ang,Zalesky, Andrew,Yue, Weihua,et al. A neuroimaging biomarker for striatal dysfunction in schizophrenia, A neuroimaging biomarker for striatal dysfunction in schizophrenia[J]. NATURE MEDICINE, NATURE MEDICINE,2020, 2020,26(26):27, 27.
APA Li, Ang.,Zalesky, Andrew.,Yue, Weihua.,Howes, Oliver.,Yan, Hao.,...&Liu, Bing.(2020).A neuroimaging biomarker for striatal dysfunction in schizophrenia.NATURE MEDICINE,26(26),27.
MLA Li, Ang,et al."A neuroimaging biomarker for striatal dysfunction in schizophrenia".NATURE MEDICINE 26.26(2020):27.

入库方式: OAI收割

来源:自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。